| NCT05614258 | Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors | RECRUITING | PHASE1 | 2023-02-13 | 2025-10 | 2025-05 |
| NCT05405595 | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2022-06-15 | 2027-04-30 | 2026-10-31 |
| NCT05277402 | ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | COMPLETED | PHASE1 | 2022-02-09 | 2022-12-01 | 2022-08-01 |
| NCT04645069 | ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2021-03-15 | 2024-05-17 | 2024-01-29 |
| NCT04775680 | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | TERMINATED | PHASE1, PHASE2 | 2021-03-11 | 2023-02-09 | 2023-02-09 |
| NCT04501276 | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-09-23 | 2025-02-01 | 2024-01-17 |
| NCT04111445 | Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors | TERMINATED | PHASE1 | 2019-08-29 | 2021-04-27 | 2021-04-27 |
| NCT03802955 | Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | COMPLETED | PHASE1 | 2018-12-20 | 2021-11-01 | 2021-11-01 |
| NCT03707093 | Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | COMPLETED | PHASE1 | 2018-09-17 | 2022-09-30 | 2022-01-24 |